Estrogens and their receptors in breast cancer progression: a dual role in cancer proliferation and invasion
- PMID: 15207254
- DOI: 10.1016/j.critrevonc.2004.02.001
Estrogens and their receptors in breast cancer progression: a dual role in cancer proliferation and invasion
Abstract
Estrogens play an important role in regulating the growth and differentiation of normal, premalignant and malignant cell types, especially breast epithelial cells, through interaction with two nuclear estrogen receptors (ERalpha and ERbeta). In this review, we present a brief overview of the actions of estrogens in the different steps of breast carcinogenesis, including cancer progression to metastasis, and of their clinical consequences in the prevention, prognosis and treatment of the disease. The requirement of estrogen receptors, mainly of the alpha subtype, in normal mammary gland differentiation and growth has been evidenced by estrogen receptor deficiency in animals. The promotion of breast cancer carcinogenesis by prolonged exposure to estrogens is well-documented and this has logically led to the use of anti-estrogens as potentially chemopreventive agents. In breast cancer progression, however, the exact roles of estrogen receptors have been less well established but they may possibly be dual. Estrogens are mitogenic in ER-positive cells and anti-estrogens are an efficient adjuvant therapy for these tumors. On the other hand, the fact that estrogens and their receptors protect against cancer cell invasiveness through distinct mechanisms in experimental models may explain why the presence of ER is associated with well-differentiated and less invasive tumors.
Similar articles
-
Estrogen receptor beta--an independent prognostic marker in estrogen receptor alpha and progesterone receptor-positive breast cancer?APMIS. 2009 Sep;117(9):644-50. doi: 10.1111/j.1600-0463.2009.02510.x. APMIS. 2009. PMID: 19703124
-
Estrogen and prostate cancer: an eclipsed truth in an androgen-dominated scenario.J Cell Biochem. 2007 Nov 1;102(4):899-911. doi: 10.1002/jcb.21529. J Cell Biochem. 2007. PMID: 17786930 Review.
-
Metastasis tumor antigen family proteins during breast cancer progression and metastasis in a reliable mouse model for human breast cancer.Clin Cancer Res. 2006 Mar 1;12(5):1479-86. doi: 10.1158/1078-0432.CCR-05-1519. Clin Cancer Res. 2006. PMID: 16533771
-
Decreased expression of estrogen receptor beta protein in proliferative preinvasive mammary tumors.Cancer Res. 2001 Mar 15;61(6):2537-41. Cancer Res. 2001. PMID: 11289127
-
[Estrogens, cathepsin D and metastasis in cancers of the breast and ovary: invasion or proliferation?].C R Seances Soc Biol Fil. 1998;192(2):241-51. C R Seances Soc Biol Fil. 1998. PMID: 9841098 Review. French.
Cited by
-
Molecular features of luminal breast cancer defined through spatial and single-cell transcriptomics.Clin Transl Med. 2024 Jan;14(1):e1548. doi: 10.1002/ctm2.1548. Clin Transl Med. 2024. PMID: 38282415 Free PMC article.
-
Cell facilitation promotes growth and survival under drug pressure in breast cancer.Nat Commun. 2023 Jun 29;14(1):3851. doi: 10.1038/s41467-023-39242-6. Nat Commun. 2023. PMID: 37386030 Free PMC article.
-
Long-term outcomes of intraoperatively-placed applicator brachytherapy for rapid completion of breast conserving treatment: An analysis of a prospective registry data.Clin Transl Radiat Oncol. 2023 May 9;41:100639. doi: 10.1016/j.ctro.2023.100639. eCollection 2023 Jul. Clin Transl Radiat Oncol. 2023. PMID: 37251618 Free PMC article.
-
The roles of FHL2 in cancer.Clin Exp Med. 2023 Nov;23(7):3113-3124. doi: 10.1007/s10238-023-01076-3. Epub 2023 Apr 27. Clin Exp Med. 2023. PMID: 37103649 Review.
-
The most likely but largely ignored triggering factor for breast (or all) cancer invasion.J Cancer. 2023 Feb 27;14(4):573-590. doi: 10.7150/jca.82291. eCollection 2023. J Cancer. 2023. PMID: 37057291 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical